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Human cytomegalovirus (HCMV) latency is typically harmless but reactivation can be
largely detrimental to immune compromised hosts. We modeled latency and reactivation
using a traceable HCMV laboratory strain expressing the Gaussia luciferase reporter
gene (HCMV/GLuc) in order to interrogate the viral modulatory effects on the human
adaptive immunity. Humanized mice with long-term (more than 17 weeks) steady human
T and B cell immune reconstitutions were infected with HCMV/GLuc and 7 weeks
later were further treated with granulocyte-colony stimulating factor (G-CSF) to induce
viral reactivations. Whole body bio-luminescence imaging analyses clearly differentiated
mice with latent viral infections vs. reactivations. Foci of vigorous viral reactivations were
detectable in liver, lymph nodes and salivary glands. The number of viral genome copies
in various tissues increased upon reactivations and were detectable in sorted human
CD14+, CD169+, and CD34+ cells. Compared with non-infected controls, mice after
infections and reactivations showed higher thymopoiesis, systemic expansion of Th, CTL,
Treg, and Tfh cells and functional antiviral T cell responses. Latent infections promoted
vast development of memory CD4+ T cells while reactivations triggered a shift toward
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effector T cells expressing PD-1. Further, reactivations prompted a marked development
of B cells, maturation of IgG+ plasma cells, and HCMV-specific antibody responses.
Multivariate statistical methods were employed using T and B cell immune phenotypic
profiles obtained with cells from several tissues of individual mice. The data was used to
identify combinations of markers that could predict an HCMV infection vs. reactivation
status. In spleen, but not in lymph nodes, higher frequencies of effector CD4+ T cells
expressing PD-1 were among the factors most suited to distinguish HCMV reactivations
from infections. These results suggest a shift from a T cell dominated immune response
during latent infections toward an exhausted T cell phenotype and active humoral
immune response upon reactivations. In sum, this novel in vivo humanized model
combined with advanced analyses highlights a dynamic system clearly specifying the
immunological spatial signatures of HCMV latency and reactivations. These signatures
can be merged as predictive biomarker clusters that can be applied in the clinical
translation of new therapies for the control of HCMV reactivation.
Keywords: HCMV, reactivation, humanized mice, T cell maturation, B cell class switch, optical imaging analyses,
principal component analyses, linear discriminant analyses
INTRODUCTION
Human cytomegalovirus (HCMV) is a ubiquitous and strict
human herpesvirus. Whereas, latency after primary infection is
mostly harmless, HCMV reactivations have been known formore
than 30 years to increase the non-relapse mortality for patients
after allogeneic hematopoietic stem cell transplantation (allo-
HSCT) (1–5). HCMV latency invokes complex mechanisms of
immune modulation and evasion such as down-regulation of the
major histocompatibility complexes (MHCs) (6–8), production
of anti-inflammatory viral cytokines (9) and T cell inflation
(MHC) (10, 11). HCMV reactivations after allo-HSCT were
shown to promote immune suppressive effects on T cells (12–
14) and, on the other hand, immune stimulatory effects on
B cells (15–17). Despite its ubiquitous and global detrimental
effects, vaccines, or immune therapies to protect against HCMV
reactivations have not been approved (18). Recapitulating the
effects of HCMV reactivation on the immune system in an in vivo
experimental system could guide toward predictive immunologic
patterns for future testing of vaccines and immune therapies in
humans.
Due to the strict species-specificity of HCMV, mouse and
primate models cannot be used to clarify the spatio-temporal
mechanisms associated with HCMV reactivations in vivo (19).
Pioneering studies by Mocarski et al utilized immune-deficient
male NOD-scid mice co-implanted with human fetal tissues
[thymus (THY), liver (LI), lung, colon and skin], and then,
largely varying from 1 to 6 months later, mice were infected
with HCMV (Toledo or Towne strains) (20). This system
showed in vivo tropism of HCMV lytic virus replications
in human epithelial cells, latency in hematopoietic cells and
confirmed antiviral effects of ganciclovir. Subsequently, Nelson
et al. further improved this HCMV infection model using
human bone marrow (BM) cells, liver and thymus tissues (also
known as BLT model) implanted into different body parts of
NOD-scid mice (21). BLT xenograft systems are known to show
a robust engraftment and early human immune reconstitution
in NOD.Cg-PrkdcscidIL-2Rγ
tm1Wjl
c (NSG) mice (22, 23), but
inopportunely, the variable early onset of xenograft GVHD
(xeno-GVHD) in this BLT model is frequently lethal (23,
24). NSG/BLT mice were injected i.p. with neonatal human
dermal fibroblasts (NHDF) infected with an HCMV and then
implanted with mini-pumps for constant human granulocyte-
colony stimulating factor (hG-CSF) release. HCMV reactivations
were shown as the increase in the numbers of genome viral copies
in peripheral blood (PBL), spleen (SPL), LI, and kidney (25).
More recently, using a short-term 12 weeks NSG/BLT model of
HCMV infection (clinical strain TRpM1A or laboratory strain
TB40/GFP), the same group detected human CD4+ and CD8+
T cell responses against the viral immediate early protein 1 (IE1)
and the phosphoprotein pp65 and humoral human responses
with the ability to neutralize HCMV in vitro (25). Nevertheless,
since proper maturation of human T and B cells require at least
15–20 weeks after human stem cell engraftment to occur (26),
the experimental design of these humanized mice studies did not
allow the evaluation of the T and B cell development. Further,
a general major obstacle of this complex NSG/BLT model is the
scarcity of fetal tissues for establishment of xenografted mice,
currently facing ethical constrains.
In order to bypass all these limitations, we explored an
alternative human reconstitution model consisting of NOD.Cg-
Rag1tm1MomIL-2Rγ
tm1Wjl
c (NRG) female mice transplanted with
largely available cord blood (CB) purified CD34+ cells. In
our hands, this robust system showed consistent long-term
(20 to more than 30 weeks) development of functional and
mature T and B cell responses (with rare incidences of
xeno-GVHD) and, when combined with dendritic cell (DC)
immunizations, we obtained patterns of predictive phenotypic
markers of immune responses (26–29). Here, we interrogated
this long-term humanized mouse model whether the immune
effects of HCMV primary infections vs. reactivations could be
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distinguished. We established a new model using an engineered
HCMV laboratory strain secreting Gaussia luciferase (GLuc)
(30) and performed non-invasive optical imaging analyses to
follow the bio-distribution and extent of viral infections. HCMV
reactivations after G-CSF administrations were confirmed by
optical imaging and genome copies analyses in different tissues.
Spatial analyses of human T and B cell development generated
immune phenotypic data demonstrating a clear divergence
between primary infections and reactivations. Reactivations were
particularly associated with up-regulation of the programmed
cell death (PD)-1 activation marker on T cells and B cell
activation. Multivariate statistical analyses such as principal
component analyses (PCA) and linear discriminant analyses
(LDA) clustered the predictive markers and corroborated
the different immunologic signatures reflecting infections and
reactivations. The parameters obtained from this predictive and
dynamic humanized mouse model system can be implemented
to test new drugs, vaccines and immune therapies aimed at
controlling HCMV reactivation.
METHODS
Ethics Statements
Umbilical CB units were obtained under written informed
consent of the mothers in accordance with study protocols
approved by Hannover Medical School Ethics Review
Board (approval Nr. 4837). All experiments involving mice
were performed in accordance with the regulations and
guidelines of the animal welfare of the State of Lower Saxony
(“Niedersächsiches Landesamt für Verbraucherschutz und
Lebensmittelsicherheit, Dezernat 33/Tierschutz,” approval Nr.
33.12-42502-04-1). Euthanasia was performed with cervical
dislocation after CO2 narcosis.
Cell Culture and Primary Cells
MRC-5 (human fetal lung fibroblasts) and HEK-293T cells
(ATCC, Manassas, VA, USA) were expanded in DMEM
(ThermoFisher, Waltham, MA) supplemented with 10% fetal
bovine serum (FBS, HyClone, Logan, UT), non-essential
amino acids (ThermoFisher) and penicillin/streptomycin (Merck
Millipore, Billerica, MA) at 37◦C with 5% CO2. Mononuclear
cells were isolated by Ficoll gradient centrifugation, CD34+
cells were purified after two rounds of immune-magnetic
bead positive selection (Miltenyi Biotech, Bergisch-Gladbach,
Germany).
Production and Titration of HCMV/GLuc
and Generation of Virus-Carrier Cells
HCMV/GLuc seeding stocks were generated using a TB40-
BAC4-cloned HCMV variant and propagated on MRC-5 cells
as described (30). Cell-free supernatants were concentrated by
centrifugation at 19,000 rpm for 2 h 20min, re-suspended in
Dulbecco’s modified Eagle medium (DMEM, ThermoFisher)
plus 1% non-essential amino acids (ThermoFisher) and stored
at −80◦C. Viral batches were titered in MRC-5 cells by
immunofluorescence analyses using the mouse anti-IE1 p63-
27 antibody essentially as described (30). For the generation
of batches of HCMV-infected carrier cells, 1.0 × 107 MRC-
5 cells were infected at a multiplicity of infection (MOI) of 1
overnight at 37◦C, the medium was replenished and then the
cells were cultivated for additional 2 days. Cells were detached
with Trypsin/EDTA (Merck Millipore), centrifuged at 300 g
for 10min, washed with PBS and cryopreserved in freezing
medium containing 15.5% human albumin, 10% DMSO (Braun,
Melsungen, Germany), and 5% glucose (Sigma-Aldrich, St.Louis,
MO). A thawed cell aliquot was stained for detection of gB on
the cell surface using the mouse anti-gB p27-287 antibody and a
secondary anti-mouse-Alexa647 antibody (Biolegend, San Diego,
CA). The frequency of gB-positive cells was determined by flow
cytometry using an LSR II cytometer (BD Bioscience, Becton
Dickinson GmbH, Heidelberg, Germany).
Bio-Luminescence Detection in Cell
Supernatants Containing Gaussia
Luciferase
Cell culture supernatants were collected and frozen at −80◦C.
Twenty microliter of thawed supernatant were mixed with 50
µl BioLux R© Gaussia Luciferase Assay Kit according to the
manufacturer’s instructions (NEB, Frankfurt amMain, Germany)
or with 50 µl 0.2µg/ml coelenterazine (Promega, Mannheim,
Germany). Bio-luminescence (light intensity per second) was
measured using an Orion II Microplate Luminometer (Titertek-
Berthold, Pforzheim, Germany) or a Tristar2 Microplate Reader
(Berthold Technologies, Bad Wildbach, Germany).
HSCT Into NRG Mice
NRGmice were obtained from The Jackson Laboratory (JAX, Bar
Harbor, ME) and bred in-house under pathogen-free conditions.
We used only female NRG mice, as we have shown that they
supported better T cell development (28) and differentiation
after DC immunizations (26). Prior to HSCT, 5 weeks-old mice
were sub-lethally irradiated (450 cGy) using a [137Cs] column
irradiator (Gammacell 3000 Elan; Best Theratronics, Ottawa,
Canada). Four hours after irradiation, 2.0 × 105 human CB-
CD34+ cells were injected into mice through the tail vein as
described (27, 29).
Infection of Humanized Mice With
HCMV/GLuc
Humanized mice were generated and analyzed essentially as
described (26–29). Frequencies of human immune cell subsets
in the PBL samples were determined at 17 weeks after HSCT.
Next, mice were treated with 150 ng mouse/day s.c. with hG-
CSF (Granocyte, Kohlpharma GmbH, Merzig, Germany) for 5
days. On the third day of hG-CSF administration, 1.0 × 106
cryopreserved/thawed viable HCMV-infected MRC-5 cells were
injected i.p. 7 weeks after infection, one cohort was treated
with hG-CSF for 7 days (2.5 mg/mouse/day s.c.) to stimulate
viral reactivations. After optical imaging analyses and euthanasia,
several tissues were collected SPL, lymph nodes (LN), mesenteric
lymph nodes (mLN), BM (flushed from two femurs), salivary
glands (SG), and LI, dissociated into single cell suspensions and
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the numbers of viable cells per tissue were quantified by trypan
blue exclusion assay.
In vivo Optical Imaging Analyses of
Humanized Mice Infected With
HCMV/GLuc
Mice were anesthetized with Ketamin/Xylazine (10 and 0.5
mg/ml, respectively, Sigma-Aldrich). Coelenterazine (Promega,
Madison, WI) was solubilized in ethanol (5 mg/ml) and diluted
shortly prior to administration in PBS (final dose 50 µg/mouse).
Mice were injected i.v. with 100 µl of coelenterazine solution
and imaged immediately. In vivo optical imaging analyses
were performed with an IVIS 200 optical imaging system
(PerkinElmer, Waltham, MA) or with an IVIS SpectrumCT
(PerkinElmer). Different CB stem cell sources were used for R1
and R2. Pictures were taken with a field of view C, f stop 1 and
medium binning for each mouse. Exposure time was set to 300 s
per mouse. The anatomical region of interest (ROI) was kept
constant for quantified analyses of all mice.
FACS Analyses
Cells obtained from peripheral blood or tissues were treated
with a hypotonic solution (0.83% ammonium chloride/20mM
HEPES, pH 7.2, for 5min at room temperature, followed by
stabilization with cold PBS and washing) in order to remove
the erythrocytes and further processed as described as fresh or
cryopreserved/thawed material for immune staining and flow
cytometry analyses (26, 29). The appropriate concentration of
each antibody was determined in the titration assay before
the main experiment. After the cells were washed to remove
unbounded antibodies and immune fluorescence was assessed
by LSR II cytometer (BD Biosciences). Commercially available
antibodies against all markers are provided in Table S1.
Quantitative Real-Time PCR (RT-q-PCR) for
Detection of HCMV DNA
Tissues were processed with the Blood and Tissue isolation kit
(Qiagen, Hilden, Germany). DNA concentration was determined
by spectrophotometry and stored at −20◦C. Twenty microliter
of the DNA sample was used for PCR analyses with an Artus R©
CMV TM PCR kit according to the manufacturer’s instructions
(Qiagen). The standard curve was determined with primers
specific for HCMV sequences and internal control primers
against a human gene. PCR was performed and analyzed with
StepOnePlus-PCR cycler (ThermoFisher). The Ct values were
used to calculate the copies of HCMV genomes per sample
adjusted with the respective DNA concentrations. For detection
of HCMV in human lymphocyte subsets, cells were sorted using
a FACS Aria 2 (BD Bioscience).
Detection of Human Immunoglobulins and
Human Cytokines in Serum
Concentrations of human Th1/Th2 cytokines in serum were
quantified by fluorescent bead–based 14-plex Luminex assay
(Merck Millipore) according to the manufacturer’s instructions.
Following human cytokines were analyzed: GM-CSF, IL-4, TNF-
α, IL-6, IL-8, MCP-1, IL-10, IL-1b, IL-5, IFN-γ, IL-7, IL-2, and
IL-12(p70). The human IgG and IgM ELISA kit (eBioscience,
San Diego, CA) was used corresponding to instructions. Serum
samples separated from peripheral blood were thawed on ice,
diluted, and samples were measured in triplicates. Plates were
analyzed with Spectramax 340PC384 plate reader (Molecular
Devices, Sunnyvale, CA).
Immunohistochemistry Analyses
Following a fixation period of 24 h in 3.7% formaldehyde buffer
(Roth, Karlsruhe, Germany) the spleen was embedded in paraffin.
Three micrometer-thick sections were prepared, dewaxed, and
subjected to immunohistological staining as described (29).
Briefly, heat-induced antigen retrieval was performed in a citrate-
buffered solution. All slides were rinsed with Tris-buffered saline
(pH 7.6) plus 0.01% Tween R©20 (Merck, Darmstadt, Germany).
Slides were incubated for 20min at 21◦C in normal goat
serum (Vector Laboratories Inc., Burlingame, CA) and then
incubated with the primary antibody (anti-human nuclei, CD3
and CD79a) for 1 h at 21◦C. Secondary biotin-SP-conjugated
antibody was applied for 30min at 21◦C. Final staining
was achieved by routine method using alkaline phosphatase
streptavidin-biotin (Vector Laboratories Inc., Burlingame, CA)
and Fast Red as chromogen (Fast Red substrate pack, BioGenex,
Freemont, CA). The slides were counterstained using Bluing
Reagent (Thermo Scientific, Braunschweig, Germany). Cover-
slipping was done using Aquatex R© aqueous mounting medium
(Merck KGaA, Darmstadt, Germany). Sample permeabilization,
antibody concentrations, antibody reactions, and staining
procedures were previously optimized for each antibody (29)
to get clear and specific immunohistochemical signals. Slides
were elevated using a bright-field microscope. Whole slides were
digitized using the Mirax scanner (Zeiss, Oberkochen, Germany)
equipped with a 20x plan-apochromat lens (Zeiss) and a camera
(Hitachi_HV_F22CL, Hitachi Kokusai Electric Europe, Neu-
Isenburg, Germany). Pictures for the figures were taken with the
Panoramic Viewer (3dHistech, Budapest, Hungary) as viewing
software.
ELISpot Analyses Using Recombinant
HCMV Antigenic Proteins
BM samples were thawed from individual mice (Exp. 4, Table 1,
CTR = 3, INF = 4, REAC = 4), and mononuclear cells
were used directly for IFN-γ ELISpot assay using the T-track
human Kit according to the vendor’s recommendations (Lophius
Bioscience, Regensburg, Germany) (31). PBMCs obtained from
HCMV sero-positive and sero-negative donors were used as
controls. Cell suspensions (2 × 105 cells/ 100 µl) were
mixed in duplicates with IE1 or pp65 recombinant proteins
(following the vendor’s recommendations, Lophius bioscience)
or with gB recombinant protein (250µg/ml, Sino Biologicals,
Beijing, China). Subsequently, the mixtures of cells plus antigens
were transferred onto ELISpot plates pre-coated with anti-
IFN-γ antibodies and incubated for 20 h at 37◦C. Immune
detection of IFN-γ spots was performed following the vendor’s
recommendations (Lophius Bioscience). Spots on the wells were
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TABLE 1 | Immune reconstitution analysis of human lymphocytes in peripheral blood of humanized mice prior to the experimental treatments.
Experiment huCD45+ (%) huCD3+inCD45+ (%) huCD4+inCD45+ (%) huCD8+inCD45+ (%)
Exp1 (week 15) , G-CSF 38.4 ± 10.1 16.1 ± 6.34 6.3 ± 2.3 4.1 ± 3.0
Exp2 (week 17) LV vs. HCMV 52.0 ± 8.0 19.1 ± 3.85 11.8 ± 2.7 6.59 ± 1.5
Exp3/R1(week 17) INF vs. REAC 27.9 ± 14.9 47 ± 10 21.3 ± 9.1 14.1 ± 4.6
Exp4/R2(week 17) INF vs. REAC 43.7 ± 10.4 10.9 ± 2.5 7.8 ± 1.4 4.9 ± 2.0
photographed and counted using a microscope and the results
depicted as spot forming cells (SFC) within 2× 105 PBMC.
ELISpot Analyses Using HCMV-Infected
Dendritic Cells
LN and mLN samples were thawed and pooled (Exp. 4, Table 1,
CTR = 3, INF = 4, REAC = 4). The corresponding CB CD34
negative fraction was used to isolate CD14+ monocytes. For the
generation of Conventional DCs (conDC), cells were cultured
in X-vivo media (Lonza, Basel, Switzerland) with recombinant
human IL-4 and GM-CSF (both 50 ng/ml; Cellgenix, Freiburg,
Germany) for 7 days. For generation of conDC infected
with HCMV-GLuc (conDC/HCMV), monocytes cultured with
cytokines for 4 days were infected with virus at M.O.I. = 1 and
maintained in culture for additional 3 days. Prior to ELISpot,
DCs were analyzed by flow cytometry to confirm expression
of relevant markers (CD80, CD86; HLA-DR, gB see Table S1).
Then, DCs and mononuclear cells (1 × 105 cells each in 100 µl)
were co-cultured on the ELISpot plate as described before for
20 h. Spots were counted automatically using an ELISpot reader
(AID, Straßberg, Germany) and the results depicted as SFC/1 ×
105 PBMC.
Dot Blot Analysis for Detection of Plasma
IgG Against gB
293T-wt and 293T-gB cells were re-suspended in PBS and
maintained on ice. Cell lysates were produced by sonication and
the protein concentration was determined with Bicinchoninic
acid assay (BCA). One microliter corresponding to 1 µg of cell
lysate was spotted onto strips of nitrocellulose membranes (GE
Healthcare, Little Chalfont, UK) and air-dried for 10min. Five
percent milk/PBS/0.05% Tween (Merck Millipore) was used to
block the membrane for 30min at room temperature. Plasma
from mice was added to the membrane strips which were
incubated overnight at 4◦C and washed 3x with PBS/0.05%
Tween for 10min at RT. Anti-human IgG-HRP (Roth, Karlsruhe,
Germany) (1:500) was added for 1 h at RT. Next, the membrane
was washed 4x with PBS/Tween for 10min at room temperature
(RT). After incubation with HRP chemiluminescent substrate
(ThermoFisher), signals were measured with a Chemidoc station
(Bio-Rad, Hercules, CA). ImageJ software (NIH, freeware) was
used for signal quantifications of dot-blots.
Quantitative ELISA for Detection of Plasma
IgG Against gB
Cell lysates were produced as described above from 293T-wt,
293T-gB,MRC-5, andMRC-5 cells infected with HCMV-GLuc (3
days post-infection,MOI= 1). After determination of the protein
concentrations, 96 well plates (Coring, Corning, NY) were coated
with 640 ng/50 µl of each cell lysate. The plates were incubated
overnight at 4◦C and washed 5x with PBS/0.1%Tween. The wells
were pre-blocked by replacing the lysates with 100 µl of PBS/5%
FBS in a wet chamber for 2 h at 37◦C and then washed 3X with
PBS/0.1% Tween. As a reference to validate the quantification
obtained with the ELISA measurements we used 50 µl a human
purified SM5-1 monoclonal antibody that was serially diluted up
to 1 × 10−4 ng/ml and applied to wells coated with the 293T-
gB lysate. The plasma samples from individual mice were diluted
at 1:10 (in PBS/2% FBS) and applied to the wells coated with
the different cell lysates. The plasma samples from each mouse
were analyzed in duplicates for each cell lysate. The plates were
incubated for 2 h at 37◦C, washed 5x with PBS/0.1% Tween and
then incubated with anti-human IgG-HRP (1:1,000) for 45min
at 37◦C. After washing 3x with PBS/0.1% Tween, 100 µl of
the TMB solution (ThermoFisher) were added to each well and
reaction was stopped with 100 µl H2SO4 (Roth). The OD450 was
measured in an ELISA plate reader.
Statistical Analyses
Data consisting of the percentage of human lymphocyte subsets
in blood and tissues and the absolute counts of different
human lymphocyte subsets in tissues (# of positive cells and %
positive) were organized in a PivotTable using Excel software
2010 (Microsoft, Redmond, WA). Each sample was coded
according to the reconstitutions (R1 or R2), cohorts (CTR,
INF, and REAC), mice IDs, time-point of analyses, tissues, and
lymphocyte subtypes. Negative binomial regression was used to
compare the cohorts in terms of total cell counts of lymphocyte
subtypes in tissues using rate ratio, whereas beta regression
was applied to compare the cohorts regarding the percentage
of human lymphocyte subsets in blood and tissues using odds
ratio. One-way analysis of variance (ANOVA) was performed
for statistical analyses to differentiate the cohorts regarding the
measurement of bio-luminescence signals after optical imaging
analyses, human cytokines in plasma, human immune globulins
in plasma, frequencies, and absolute counts of Tregs and Tfh
cells and the determination of viral neutralization in vitro.
Parameter estimation was performed by least square means.
P-values were calculated at significance levels 0.05 using two-
sided t-test statistical analyses (estimated p-values lower than 0.01
have been indicated). All analyses were implemented using the
SAS 9.3 software (SAS, Cary, NC). PROC GENMOD and PROC
GLIMMIX procedures were used for the negative binomial and
beta regression analysis, respectively. GraphPad Prism version
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5 software (GraphPad Software, Inc., La Jolla, CA) was used to
create all figures.
Principal Component and Linear
Discriminant Analyses
Principal component analysis (PCA) is a multivariate
statistical technique used to simplify high-dimensional data by
emphasizing the data variations. PCA expresses the underlying
information in data with a new set of variables called principal
components (PC). PCs specify directions where the data is
widely distributed and a significant proportion of data variability
can be explained. By calculating the correlation of original data
with the PCs, one can identify the markers with the highest
correlation/anti-correlation value. We employed PCA in our
experimental data to identify a subset of markers accounted
for data variations. The relationship between the identified
markers was obtained by calculating their correlations. Our
analysis consisted of the following steps: (1) variables (markers)
were standardized, i.e., normalized with 0 mean value and
unit variance; (2) PCA was performed on different subsets
of experimental data according to the unit [absolute (#)vs.
frequency (%)], cell-type (T-cell vs. B-cell associated markers),
and organ (LN, SPL, BM, single-organ/multi-organs); (3) most
important T cell and B cell associated markers with highest
maximum correlation with the first 3 PCs were selected; (4)
correlations between markers were calculated and presented
in the form of heat-maps. In order to find the PCs that could
distinguish individuals according to their group (control, after
HCMV infections, or reactivations), we searched for PCs (among
top 5 PCs) that could separate the distribution of samples of
distinct groups. Then, the markers with highest contribution
to the composition of the separating PCs were obtained as the
potential predictors of the group.
Linear Discriminant analysis (LDA) is a multivariate statistical
technique for data profiling and clustering which aims to find
a linear combination of variables that best separates samples of
distinct groups. LDA creates discriminant functions maximizing
the “between-class” separability while minimizing the “within-
class” variability. We employed LDA on the experimental
data to identify top markers that are contributing in the
separability of groups. The most important markers for group
discrimination were identified according to the contribution
of markers in the composition of discriminant functions (the
absolute value of associated coefficient). PCA and LDA were
performed with 23 observations (7 CTR, 8 INF, 8 REAC) with 130
phenotypic markers (65 absolute numbers and 65 frequencies)
using FactoMineR (32) and MASS (33) libraries of the statistical
computing software R (version 3.4.3) (34).
RESULTS
huNRG Mice Show Reproducible and
Robust HCMV-GLuc Infections and
Reactivations
We explored the use of the novel HCMV/GLuc strain expressing
the Gaussia luciferase reporter gene downstream of the IE1
promoter (30). This promoter is strongly active immediately
after HCMV infection, and thus IE1 expression is suitable for
determining HCMV infection in several types of cells, including
peripheral blood mononuclear cells (PBMCs) (Figure S1A). A
high correlation between inoculation dose and bio-luminescence
signal was measured 1 day post-infection of MRC-5 fibroblasts
with the HCMV/GLuc at MOIs 10−4 to 102 (Figure S1B).
Cryopreserved batches of HCMV/GLuc-infected MRC-5 cells
were produced and, after thawing, flow cytometry analyses
showed that 70–90% of the viable cells expressed the HCMV
glycoprotein B (gB) on the cell surface (Figures S1C,D).
G-CSF is known to mobilize and activate stem cells and
myeloid precursors, thereby promotingHCMV infection. In pilot
experiments we evaluated the immune modulatory effects of hG-
CSF on mice transplanted with human CD34+ cells (Figure 1).
Importantly, we utilized only banked and cryopreserved CD34+
purified cells pre-tested in couple of transplanted NRG mice
showing robust long-term (>15 weeks) human reconstitutions.
In our laboratory, a sufficient “humanization” is arbitrarily
defined by the presence of >20% human CD45+ cells within
all PBMCs measured at 15 weeks after CB-HSCT or prior to
the experimental start. Seventeen weeks after HSCTs, human cell
frequencies analyzed in PBL for the four different experiments
described below varied: 28–52% huCD45+; 11–47% huCD3+ in
huCD45+; 6–21% huCD4+ in huCD45+, and 4–14% huCD8+ in
huCD45+ (Table 1). Despite this variability among the different
experiments, these values were within our expected ranges.
At 17 weeks after HSCT, humanized mice were administered
subcutaneously and daily for 5 days with a low dose of hG-CSF
(150 ng). Twenty-four weeks after HSCT, prior to experimental
termination, mice were administered with a high dose for 7
days (2.5 µg/mouse/day) (Figure S1E). Flow cytometry analyses
of CD45+, CD19+, CD3+, CD4+, CD8+ cells performed at 25
weeks post-HSCT showed that the hG-CSF treatment schedule
on its own did not affect the development or expansion of human
lymphocytes in SPL or BM when compared to transplantation
only controls (CTR) (Figure S1F).
Next, we used the same hG-CSF treatment schedule but
combined it with HCMV infections (reconstitution data analyzed
for PBL shown inTable 1, Exp 2).We established a cryopreserved
stock of MRC-5 cells infected with a lentiviral vector (LV)
expressing GLuc (MRC5-LV) and a cryopreserved stock of
MRC-5 cells infected with HCMV/GLuc. After thawing and
serially diluting the cell stocks in a 96 well plate, we confirmed
equivalent levels of bio-luminescence by optical imaging analyses
(Figure 1A). Humanized NRG mice at 17 weeks after CD34+
HSCTwere administered with 1x106 MRC-5-LV cells (n= 4) and
then treated with hG-CSF daily from weeks 24 to 25. These mice
showed only background bio-luminescence signals detectable on
weeks 21 and 25, similar to the transplantation only controls
(CTR, n= 2) (Figure 1B). This indicated that the MRC-5 cell did
not engraft in the mice and basically disappeared. In contrast, all
mice injected with 1 × 106 HCMV/GLuc-infected MRC-5 cells
(HCMV-REAC, n = 4) showed conspicuous bio-luminescence
signals in the ventral anatomical regions, indicating ongoing
viral reactivations (Figure 1B). Compared to the MRC-5-LV
cohort, mice with HCMV reactivations exhibited higher absolute
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FIGURE 1 | Infection of NRG mice with mock MRC-5 and HCMV-MRC-5 cells followed by stimulation with hG-CSF. (A) Schematic representation of experiment 2.
MRC-5 transduced with LV-GLuc and MRC-5 infected with HCMV-GLuc showing comparable bio-luminescence signal by optical imaging analyses. As a control
group (CTR), irradiated NOD.Rag−/− IL2γcR
−/− (NRG) mice were transplanted with CD34+ CB-HSCT and maintained for 25 weeks. At week 17 after HSCT,
experimental groups were treated with hG-CSF (150 ng/mouse/day s.c.) for 5 days and injected i.p. with 1 × 106 MRC-5-LV-GLuc cells (LV) or with
MRC-5-HCMV-GLuc cells (HCMV); at week 24 after HSCT they were treated for 7 days with hG-CSF (2.5 µg/mouse/day s.c.). (B) Optical imaging analyses
performed at weeks 21 and 25 after HSCT showing bio-luminescence signals on different body parts of MRC-5-HCMV-GLuc injected mice (scale bar depicts the
(Continued)
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FIGURE 1 | average radiance as p/s/cm2/sr). (C) Quantified total cell numbers (# of positive cells) of human cells recovered from SPL and BM: huCD45+ cells within
all lymphocytes or CD19+ B cells, CD3+, CD4+, and CD8+ T cells within huCD45+ cells. Bar graphs represent CTR (white bars), LV (gray bars), and HCMV (black
bars) mice. (D) Total cell numbers (# of positive cells) are shown for CD4+ T cells (left) and CD8+ T cells (right) for different subtypes (N, CM, EM, TE) for SPL (top) and
BM (bottom). (E) Total cell numbers (# of positive cells) for PD-1 expression on CD3+, CD4+, and CD8+ T cells in SPL (top) and BM (bottom). (F) Analysis of B cell
maturation showing IgMmBC, IgGmBC (left, IgM+, and IgG+ memory B cells), PB, and PC (right, plasmablasts, and plasma cells) for SPL (top) and BM (bottom).
Statistics were performed with unpaired T-test comparing MRC-5-LV and HCMV-REAC (* <0.05; ** <0.01; *** <0.001).
numbers of CD3+, CD4+, and CD8+ T cells in SPL and
BM (Figure 1C, see gating strategy in Figure S2A). We further
defined the CD3+ T cell maturation subtypes based on the
expression of CD62L and CD45RA as previously described (35):
naïve (N, 62L+, and RA+), central memory (CM, 62L+, and
RA−), effector memory (EM, 62L−, and RA−), and terminal
effector (TE, 62L−, and RA+) (see gating strategy in Figure S2B).
Upon HCMV reactivations, the immune phenotype profiles of
the CD4+ T cells from SPL and BM showed a pronounced
elevation in the absolute numbers of central memory (CM)
and effector memory (EM) cells (Figure 1D, S1G). Additional
examination of T cells in these tissues through expression
analyses of PD-1 revealed that HCMV reactivations stimulated
both CD4+ and CD8+ T cell activations Figure 1E, S1G.
Remarkably, analyses of B cell markers indicative of class
switch showed that HCMV reactivations were associated with
major rises in the numbers of mature IgG+ memory B cells
(IgGmBC), plasma blasts (PB, CD138neg), and plasma cells
(PC, CD138pos) (Figure 1F, Figure S1H) (see gating strategy
in Figures S2C,D). Thus, collectively, this data established the
set-up and feasibility of the model recapitulating HCMV/GLuc
reactivations, introduced the usage of spatial optical imaging
analyses to track viral bio-distribution and showed associations
between the HCMV reactivations with T and B cell activations.
For the subsequent experiments with larger mice cohorts
for in-depth immunological analyses, we compared the effects
of HCMV reactivations with primary latent infections. Thus,
in addition to the G-CSF double treatment schedule (REAC,
n = 8), we included one latent infection cohort which did
not receive the second hG-CSF daily administrations between
weeks 24 and 25 (INF, n = 8) (Figure 2A). Mice transplanted
with HSCs but not treated were used as baseline control
(CTR, n = 7). Experiments were performed in duplicate
with mice reconstituted with CD34+ cells obtained from two
different CB donors (Table 1, Exp 3/R1 and Exp 3/R2). Optical
imaging analysis performed prior to euthanasia demonstrated
high bio-luminescence signals after HCMV infections, which
increased after reactivations (Figure 2B). The bio-distribution
of the bio-luminescence ranged from speckled signals in the
abdominal region to intense spots in the anatomical regions
of SG, LI, and LN (Figure 2B). No major changes in body
weight were observed after primary HCMV infections or after
reactivations (Figure 2C), and no signs of xeno-GVHD were
observed macroscopically. HCMV viral DNA was detected in
LI of all infected mice (average 104 viral copies/µg DNA),
which increased substantially after reactivations (average 106
viral copies/µg DNA) (Figure 2D). This increase was also
observed in SPL and BM, but was less pronounced. Further
confirming the optical imaging bio-distribution analyses, HCMV
DNA copies were detectable in LN and SG of some of the
mice and at higher levels after HCMV reactivations (Figure 2D).
Remarkably, although all mice were infected, HCMV DNA
was inconsistently detected in PBMCs of blood (PBL), i.e., in
only about half of the mice after infections and reactivations
(Figure 2D). We were able to detect HCMV DNA only in
monocytes (CD45+/CD14+) sorted from spleen after primary
infections (INF) but not after reactivations (Figure 2E). On the
other hand, we detected HCMV DNA in sorted macrophages
(CD45+/CD169+) after reactivations (REAC), but not after
primary infections (INF) only (Figure 2E). CD34+ cells, known
to become latently infected with HCMV (36), also showed
HCMV DNA copies after infections, which increased upon
reactivations (Figure 2F). Thus, whereas analyses of BL were
not accurate (i.e., showing frequently false negatives values),
viral copy numbers in LI, BM, SPL, LN, and SG and in sorted
CD34+ cells and monocytes were consistently higher after
reactivations. Histology analyses revealed that the spleens of
infected and reactivated mice were enlarged with clear follicle
formations containing human T (CD3+) and B (CD79a+) cells
(Figure 2G). Immune histochemical analyses of LI for detection
of human nuclei (HN) showed higher rates of human cells in
infected and reactivatedmice than in controls, but the occurrence
of HCMV/IE1+ cells was rare (Figure 2H). All together,
these results demonstrated robust qualitative and quantitative
differences between HCMV infections and reactivations in this
humanized mouse model, providing in addition comprehensible
bio-distribution information by non-invasive imaging analyses.
Human T Cells and Cytokines in Blood Are
Moderately Modulated by HCMV
We next tried to detect immune effects of HCMV infections and
reactivations in BL samples that were obtained longitudinally.
Whereas, there was only a slight decline in hCD45+ frequencies
in the CTR and INF groups in the period between 17
and 25 weeks (to 30%), a prominent drop was detectable
after reactivations (to 15%) (data did not reach statistical
significance) (Figure S3A). But other than that, the relative
frequency of B cells, CD4+ T, and CD8+ T within huCD45+
PBL were not much different among the experimental groups
(Figures S3B–D). Regarding the T cell maturation subtypes
in blood, only the relative frequencies of CD4+ and CD8+
CM T cells were moderately increased after primary infections,
but this effect disappeared after subsequent reactivations
(Figures S3E,F). Analyses of human cytokines in plasma revealed
that, compared with the other groups, infected mice contained
lower concentrations of two important Th1-type cytokines,
namely IFN-γ (INF Vs. CTR p = 0.07 and INF Vs. REAC
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FIGURE 2 | Infections of humanized mice with the HCMV/GLuc strain followed by reactivations stimulated by hG-CSF. (A) Schematic representation of experiments 3
and 4. CB-HSCT was performed for generation of control mice (CTR, n = 7) using 2.0 × 105 CD34+ cells injected i.v. into NRG mice. For the infection group (INF,
n = 8) 1 × 106 MRC-5 cells infected with HCMV/GLuc were injected i.p. and received 150 ng hG-CSF administered s.c. for 5 days, at week 17. For the reactivation
cohort, (REAC, n = 8), 2.5 µg hG-CSF were administered s.c. daily for 7 days after week 24. (B) Representative pictures obtained from optical imaging analysis for
(Continued)
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FIGURE 2 | each group (scale bar depicts the average radiance as p/s/cm2/sr) and quantified data analyzed by applying the same region of interest (ROI) for each
mouse. Statistical analyses were performed with one-way ANOVA (** <0.01). (C) Weekly weight monitoring of mice for each cohort from week 15 to 25 after HSCT for
CTR (black), INF (red) REAC (blue). (D) RT-q-PCR analysis for detection of HCMV DNA in LI, SPL, BM, LN, SG, and PBL depicted as log10 copies/µg DNA. Cohort
sizes (n) analyzed for each tissue are shown and no detected (N.D.) HCMV DNA for CTR mice. (E) Cells from SPL of two mice per cohort were sorted for selection of
CD14+CD169− monocytes, CD14−CD169+ macrophages, or the double negative CD14−CD169− fraction. HCMV DNA copies were detected by RT-q-PCR and
results for each cohort are shown. (F) CD34+ cells were sorted from BM samples. HCMV DNA copies were detected by RT-q-PCR and results for each cohort are
shown. (G) Immuno-histopathological analysis of spleen for detection of human cell nuclei (anti-HN), T cells (anti-CD3), and B cells (anti-CD79a). The arrows point to
small follicles in representative CTR mouse and enlarged follicles for INF and REAC representative mice. (H) Immuno-histopathological analyses of LI. Arrows point to
stained human cell nuclei (HN) for representative CTR, INF, and REAC mice. LI of a REAC mouse with an infected cell expressing HCMV-IE1. Size bars at upper left
corners correspond to 50µm.
p = 0.11) and IL-12 (n.s.). On the other hand, analyses of IL-
10, which is a typical Th2-type cytokine, showed a moderate
increase after HCMV infections, but more so after reactivations
(n.s.) (Figure 3A, Table S2). Thus, overall, the HCMV immune
modulatory effects observed in circulating lymphocytes and
plasma of humanized mice were mild.
HCMV Primary Infections and
Reactivations Boost T Development in
Thymus and T Cell Expansion in Lymphatic
and Infected Tissues
We next examined the effects of HCMV infections and
reactivations on the T and B cell lineages in primary and
secondary lymphatic tissues and several organs for comparative
analysis. For comparative analyses, we mostly adopted the
absolute human lymphocytes counts, since we showed previously
that they were more suitable than relative cell frequencies to
reliably characterize immune modulations (26). For thymus,
HCMV infections and reactivations stimulated higher hCD45
cellularity and higher absolute numbers of CD4/CD8 double
negative (DN, REAC vs. CTR p= 0.02), double positive (DP, n.s.),
and CD4 single positive (CD4SP, INF vs. CTR p= 0.01, REAC vs.
CTR p= 0.01) T cells (Figure 3B,Table S3). For LN, significantly
increased numbers of hCD45+ cells (INF Vs. CTR p= 0.04, INF
Vs. REAC p = 0.03), CD3+ (INF Vs. CTR p = 0.03, INF Vs.
REAC p = 0.02), CD4+ (INF Vs. CTR p = 0.03, INF Vs. REAC
p = 0.03), and CD8+ T cells (INF Vs. CTR p = 0.04, INF Vs.
REAC p= 0.02) were observed after HCMV infections compared
with the other groups. Similar trends were observed for SPL,
BM, and SG (Figure 3C, Table S4). After HCMV infections, and
more markedly after reactivations, the numbers of PD-1+ T cells
were consistently increased for several tissues (Figure 3D: LN,
BM, SG; Figure S3: LI and mLN; Table S5). Noteworthy, HCMV
infections and reactivations also promoted significantly higher
frequencies of CD4+/CD25+/FoxP3+/CD45RA− regulatory T
cells (Tregs) (INF Vs. CTR p < 0.05, REAC Vs. CTR p < 0.05)
and CD4+/PD-1+/CXCR5+ T follicular helper cells (Tfh) (INF
Vs. CTR p < 0.05, REAC Vs. CTR p < 0.05) in SPL (Figure 3E).
In order to check for functional T cell responses against
HCMV antigens, lymphocytes recovered from bone marrow
were assayed by IFN-γ ELISpot using pp65, IE1, and gB
recombinant proteins as antigens (Figure 3F). Blood cells of
healthy donors known to be HCMV seropositive (HD+) or
seronegative (HD−) were used as controls to validate the assay.
No reactive spots could be detected with cells retrieved from
CTR mice (n = 3), whereas T cells recovered from mice after
HCMV infections (n = 3) and reactivations (n = 3) showed
detectable spots. Since the detectable number of SFCs was very
low using this antigen-specific assay (in the range of 3–12 SFCs
per 2 × 105 PBMCs) and we could not differentiate if the
responses in mice undergoing HCMV infection or reactivation
were distinguishable, we developed another more robust ELISpot
assay. We had previously shown that conventional dendritic cells
(conDCs) obtained upon culture of monocytes with GM-CSF
and IL-4 could be efficiently infected with HCMV laboratory
strains (37). Therefore, we generated conDCs matched with the
CB CD34+ cells used to humanize the mice and infected them
with HCMV/GLuc (Figure 3G; as control for the assay, we used
non-infected conDCs). Mononuclear cells present in pooled LN
and mLN samples (CTR = 3, INF = 4, REAC = 4) were
co-cultured with the HCMV-infected or non-infected conDCs
on the ELISpot plate for 20 h. Background reactivity due to
homeostatic stimulation was detectable for all co-cultures with
conDCs. Nevertheless, comparing the number of spots observed
when the assay was performed with conDC/HCMV and using
effector cells from mice undergoing HCMV infections, we
obtained almost 300 SFCs per 1 × 105 PBMCs, and these
numbers were half as high for mice undergoing reactivations.
Thus, the results obtained with this ELISpot assay seem to
provide an inverse correlation between the elevated numbers
of PD-1+ T cells after HCMV reactivations with lower T cell
responses against the HCMV-gB antigen. Since the T cells that
develop in these humanize mice are not expected to be restricted
to the humanHLA, the use of tetramer analyses to verify the PD-1
upregulation on HCMV-specific T cells cannot be explored.
Reactivations Promote the Development of
Memory and Terminal Effector T Cells
Expressing PD-1 in Spleen, but not in
Lymph Node
Moving toward a more in-depth and complex analyses of the T
cell signatures in tissues, we assessed the correlations between T
cell immune phenotypic patterns with PD-1 expression (gating
strategy provided in Figure S2). LN contained the highest
numbers of CM and EM CD4+ and CD8+ T cells after HCMV
infections (Figure 4A, Tables S6A–D, Figure S4A). The PD-1
expression pattern within the T cell subtypes in LN was between
INF and REAC, but for T effector T cells of the INF cohort,
PD-1 expression was lower. After HCMV reactivations, the
numbers of TE CD4+ cells were significantly increased in SPL,
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FIGURE 3 | Detection of human cytokines, T cell distribution in different lymphatic and non-lymphatic tissues plus, TREGs, T-FH and functional T cell responses
against HCMV. (A) Luminex bead-array obtained concentration (pg/ml) of human IFN-γ, IL-12, and IL-10 in mouse plasma. (B) Quantified total cell numbers (# of
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FIGURE 3 | positive cells) of huCD45+ cells within all lymphocytes, CD3+ T cells within huCD45+, and DN, DP, CD4SP, and CD8SP within CD3+ T cells.
(C) Quantified total cell numbers (# of positive cells) of huCD45+ cells within all lymphocytes, CD3+ T cells within huCD45+, and CD4+ and CD8+ within CD45+ T
cells for SPL, LN, BM, and SG. Bar graphs represent CTR (white bars), INF (gray bars), and reactivated (REAC, black bars) mice. Reconstitutions included in analysis
are indicated (R1+R2: CTR n = 7, INF n = 8, REAC n = 8; R2: CTR n = 3, INF n = 4, REAC n = 4). Error bars represent standard error of the mean. Negative
binomial-regression model was applied for statistical analysis (* <0.05). (D) Total cell numbers (# of positive cells) (top panel) and mean fluorescent intensity (MFI,
bottom panel) for PD-1 expression on CD3+, CD4+, and CD8+ T cells in SPL (R1+R2), LN (R2), BM (R2), and SG (R2). Negative binomal-regression model was
applied for statistical analysis (* <0.05; ** <0.01). (E) Top Panel: Percentage of FoxP3+/CD45RA− regulatory T cells; lower panel: Percentage of PD-1+/CXCR5+
FTh cells in SPL of individual mice analyzed in R2 corresponding to CTR (white dots), INF (gray dots), and REAC (black dots). One-way ANOVA with Turkey test was
used for statistical analysis (* <0.05). (F) IFN-γ ELISpot assay performed with cells recovered from BM (Exp.4) stimulated with proteins. BM samples from mice in
each cohort (CTR n = 3, INF n = 3 and REAC n = 3) were stimulated in duplicates with HCMV pp65, HCMV IE1 and HCMV gB recombinant proteins. N.D. depicts
non-detectable spots. An HCMV sero-positive donor (HD+) and a sero-negative (HD−) were used as references. Results are depicted in spot-forming cells (SFC) per
2 × 105 PBMC. (G) IFN-γ ELISpot assay performed with cells recovered from LN and mLN (Exp.4) were stimulated with HCMV-infected dendritic cells. Upper panels:
Flow cytometry analyses of conventional DCs (conDC) or HCMV-infected conDC (con/HCMV) showing gB expression in the later. Lower panel: Pooled samples
obtained from mice in each cohort were co-incubated with conDC or conDC/HCMV in duplicates. N.D. depicts non-detectable spots. HD+ and HD− were used as
references. Results are depicted in SFC per 1 × 105 PBMC and bar graphs represent the mean values for duplicates.
BM, and SG, and this was associated with high numbers of
CD4+ PD-1+ cells (Figure 4A, Tables S6A–D, Figures S3, S4A).
Therefore, LN seemed to represent a distinct tissue regarding
immunomodulation of T cells by HCMV. In general terms,
these analyses emphasized the relevance of specific niches such
as LN for central T cell memory homeostasis vs. SPL, BM,
mLN, and LI for T cell activations toward PD-1+ activated
effector T cells. Thus, the allocation of T cells with different
maturation and activation status within different tissues showed
a very complex pattern, likely defined by multifactorial variables.
To dissect structural relationships (trends) between phenotypic
markers and to uncover their changes according to the HCMV
infection status, we employed PCA and correlation analyses. This
approach evaluates any possible relationship between variables
and its alteration (lost, formed or inversed) between the groups
(CTR, INF, REAC). Due to a large set of measured quantities, we
first employed PCA to identify the markers that best explain the
data variations. This was achieved by considering all the groups
simultaneously (INF, REAC, CTR).We tested all combinations of
data subsets according to the organ and the type ofmeasurements
(frequencies, absolute numbers, B cell, or T cell associated
markers), and only showed the data subsets that could enlighten
the different groups.
Using the absolute (#) or frequency (%) of T cell associated
markers in LN, we found two PCs that moderately separated
REAC from INF and CTR groups. Terminal effector (#) and
effectormemory (%) CD4+ T cells in LNwere importantmarkers
in these separating PCs (Figure 4B). The markers with absolute
numbers gave a better separation of REAC group from INF
and CTR compared to the frequencies, yet, the variation of the
whole data was much smaller (compare the range of y-axis in
Figure 4B). A separation of REAC from CTR and INF group
could also be obtained using the SPL data (Figure 4D). Several
importantmarkers that contributed to these PCs contained PD-1.
Then, the correlation analyses were performed between markers
(absolute numbers #) within each group and the comparisons
were depicted in the form of heat-maps (Figures 4C,E). The LN
data of the INF and REAC groups were almost undistinguishable
(Figure 4C), whereas the BM and SPL data showed clearly
different interrelations of phenotypic markers between REAC vs.
INF (Figure 4E). In sum, the PCA combined with the correlation
analyses applied for immune modulation of T cells in SPL
and BM distinguished reactivations from infections through a
signature of memory and terminal effector T cells expressing the
activation marker PD-1. This signature was less evident for LN
data, where other markers such as CD19 were overrepresented
for the REAC cohort.
HCMV Reactivations Boost IgG+ Memory
B Cells and Plasma Cells
Next, we evaluated the effects of HCMV infections and
reactivations on the B cell development, maturation and class
switch (Figure 5, Tables S7A,B). The B cell antigen CD19
assembles with the B cell receptor (BCR) and is continuously
expressed along the different stages of early B cell development
but it is lost upon maturation to plasma cells. On the other
hand, CD27 is a later B cell marker, which is the ligand for
CD70, and plays a key role in regulating B-cell activation and
immunoglobulin synthesis. Since B cells initially develop in
BM, this was the tissue initially analyzed. As expected, most
of the B cells there were immature (CD19pos/CD27neg), and
could be further sub-grouped in immature/ transitional type 1
(T1, CD24hi/CD38hi) (Figure S5B) cells, transitional type 2 (T2,
CD24int/CD38int), mature naïve (MNBC, CD24low/CD38low),
and pre-memory B cells (pre-mBC, CD24pos/CD38neg), whereas
very few plasma blasts (PB, CD138neg), plasma cells (PC,
CD138pos), and IgG+ cells could be detected (see gating strategy
in Figure S2). Most of the detected CD19pos/ CD27pos B cells
in BM were IgM+ but IgG+ cells were also detectable. Thus,
HCMV infections and reactivations did not alter much the
pattern of B cell development in BM. In contrast, reactivations
pushed the development and maturation of B cells in SPL,
resulting in higher numbers of T1 (REAC vs. CTR p = 0.01,
Table S7A), T2 (REAC vs. CTR p= 0.03, Table S7A), PB (REAC
vs. CTR p = 0.03, Table S7B), and IgG+ B cells (REAC vs.
CTR p = 0.01, Figure 5A, Table S7B, Figure S6A). The effects
of HCMV reactivations obtained for SPL were in line with the
results obtained for mLN and LI (Table S7B, Figures 5B). In
contrast, LN showed a deviant pattern, as primary infections
suppressed the development of IgG+ memory B cells (REAC vs.
INF p < 0.01, Table S7B, Figure 5A) and reactivations pushed
significantly the development of mature PB, PC, and IgG+ B
cells (Figure 5A, Table S7B, Figure S6A). A PCA performed
with B cell associated markers using absolute cell numbers (#) in
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FIGURE 4 | Differentiation of CD4+ and CD8+ T cell subsets after HCMV infections and reactivations and PCA analysis. (A) Total cell numbers (# of positive cells) are
shown for CD4+ T cells (left) and CD8+ T cells (middle) for different subtypes (N, CM, EM, TE) and activation (PD-1+) (right) analyzed in CTR (white bars), INF (gray
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FIGURE 4 | bars), or REAC (black bars) cohorts for LN, SPL, and BM. Reconstitutions included in the analysis are indicated (R1+R2: CTR n = 7, INF n = 8, REAC
n = 8). Negative binomal-regression model was applied for statistical analysis (* <0.05; ** <0.01). (B,C) PCA analysis of T cell-associated markers with absolute
numbers (#) was performed according to the materials and methods. Selected markers are sorted vertically (descending order) based on their maximum correlation
with the first 3 principal components. Correlations between markers in (B) LN, and (C) combined measurements from SPL (blue) and BM (black) are shown for
different groups of mice. (B,C) PCA performed with T cell-associated markers including absolute numbers (#) and frequencies (%) in LN was performed according to
the materials and methods. (B) Distribution of the individual measurements in each group is shown for PC3 and PC4 as box-plots. The percentage of the data
variation explained by each PC is given in the y-axis. The top 5 (ordered) markers contributing to the composition of each PC and their correlation with each PC are
given. Positive and negative values of correlation coefficient are coded with red and blue texts, respectively. (C) Markers with highest maximum correlation with the
first 3 PCs are selected and ordered vertically. Correlation between these markers is shown for INF and REAC groups as heat-maps. (D,E) The same analysis as in
(B,C) was performed with T-cell associated absolute (#) and frequency (%) measurements in SPL (D) and using a combined data set of absolute numbers (#) of T-cell
associated markers in SPL (marked with asterisk) and BM (E).
SPL resulted in two separating PCs, which clearly distinguished
REAC group from the other groups (Figure 5B). The phenotypic
markers in PC1 (pre-MBC, PB, IgM+, PC, and CD19+CD27+)
and PC4 (IgG+, T1 BC, and IgM+) were among the markers
overrepresented in the REAC group. Therefore, the heat map
based on the SPL data clearly showed different interrelations of
phenotypic B cell markers in REAC vs. CTR (Figure 5C).
Reactivations Boost IgGs Against
HCMV-gB
We further evaluated whether the distinctive B cell-related
immune phenotypic patterns associated with HCMV
reactivations correlated with functional antibody generation.
Levels of human IgM and IgG in plasma were both higher after
HCMV reactivations (figure 5D, Table S8). The levels of human
IgG (determined by least square mean estimation, LSM) were
considerably higher after reactivations (27.89µg/ml) relative
to controls (15.37µg/ml) or primary infections (6.44µg/ml).
In order to evaluate reactivity of human IgGs recovered from
plasma against HCMV-gB, dot-blots using protein extracts
obtained from wild type (w.t.) 293T cells and 293T cells
expressing gB were used for immune detection (Figure 5E). No
signs of IgG reactivity against gB could be found in plasma of
control mice. Plasma obtained frommice after HCMV infections
showed detectable reactivity, which was further enhanced
with plasma from mice after HCMV reactivations. Further,
an ELISA assay was developed in order to provide additional
evidence by other methods that mice infected with HCMV and
undergoing reactivations could mount IgG responses against
HCMV (Figure 5F). ELISA plates were coated with protein
lysates generated with 293Twt, 293TgB, MRC-5 cells, or MRC-5
cells infected with HCMV. As a reference for the assay we used
a high affinity purified human monoclonal antibody recognizing
gB (SM5-1). Plasma samples from mice obtained in experiment
#2 (receiving either MRC-5/LV-GLuc or MRC-5/HCMV-GLuc)
were diluted 10-fold and applied to the wells of the plates. The
results showed clearly that plasma obtained from several mice
undergoing HCMV reactivation reacted against proteins present
in 293TgB and in MRC-5 cells infected with HCMV. Only
background signals were obtained for plasma obtained from
mice administered with MRC-5 cells infected with LV-GLuc.
These results confirmed the data shown by Crawford et al using
other ELISA methods (25) that humanized mice infected with
HCMV can mount detectable IgG responses.
LDA Analyses Allowed a Decisive
Representation of T and B Cell Signatures
As another strategy to reduce the complexity of our data and
find phenotypic markers that might be essential for defining
HCMV infections vs. reactivations status, we employed LDA on
our experimental data in similar fashion to PCA (see Methods).
LDA performed with a subset of measurements (frequencies
and/or absolute values) obtained from the T and B cell panels
(individually or combined) resulted into distinct separations of
CTR, INF, and REAC groups (Figure 6A). LDA analyses using
only the frequencies of T lymphocyte types in blood identified
clusters for each experimental arm, but with some overlap. When
the frequencies and absolute numbers of T lymphocyte types in
spleen were used in combination, the experimental arms could
be better divided. Nevertheless, LDA performed with frequencies
and absolute numbers of the B cell panel clearly showed the
best distinction among the clustered groups. However, when
the data obtained with B and T cell panels were combined, the
clustering was less prominent, indicating that data obtained from
T and B panels were not additive or synergistic. In summary, the
LDA analyses advocated that using different subsets of immune
phenotypic markers, and predominantly the B cell panel, mice
with HCMV infections and reactivations could be distinctively
distinguished from the control group.
DISCUSSION
Prior studies based on humanized models demonstrated HCMV
infections and reactivations in vivo (20, 21, 25), but did not
address their differences regarding tissue-dependent patterns of
T and B cell development, differentiation and activation. Here, we
described a practical, robust and reliable in vivomodel discerning
the effects of HCMV primary infections and reactivations on
human T and B cell immune modulations and their functional
responses against HCMV antigens. Our model takes a simplified
approach for studying HCMV infections in vivo model using
NRG female mice transplanted with CB purified CD34+ cells.
When human T cell immune reconstitution stabilized at 17 weeks
post-transplantation, cell carriers infected with HCMV/GLuc
were administered and viral reactivations were promoted by
hG-CSF administration. Expression of Gaussia luciferase as a
reporter gene inserted downstream of the IE1 promoter into the
HCMV genome allowed non-invasive bio-distribution analyses
of viral dissemination and reactivations. The combination of
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FIGURE 5 | Differentiation of B cell subsets and class switch after HCMV infections and reactivations with HCMV specific IgG response. (A) Total cell counts (# of
positive cells) are shown for B cells obtained from control (CTR, white bars), infected (INF, gray bars), or reactivated (REAC, black bars) cohorts in different tissues: LN
(R2), SPL (R1+R2), and BM (R2). Error bars indicate standard error of the mean. Negative binomial-regression model was applied for statistical analysis (* <0.05;
** <0.01). (B) Similar PCA and correlation analyses to Figures 4B,C is shown for B cell associated markers with absolute numbers (#) in SPL. (B,C) PCA performed
(Continued)
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FIGURE 5 | with B cell-associated markers consisting of absolute numbers (#) in SPL was performed according to the materials and methods. (B) Similar analysis as
Figures 4B,D was performed and the individual measurements are shown according to their values in PC1 and PC4. (C) Similar correlation analysis as Figures 4C,E
is presented in the form of heat-map for CTR and REAC groups. (D) Total human IgM and IgG (µg/ml) measured in plasma by ELISA for CTR (n = 7), INF (n = 7), and
REAC (n = 7) cohorts. (E) Dot-blot assays. Plasma from HCMV infected mice was tested for reactivity against HCMV-gB based on cell extracts of 293T-w.t. and
293T-gB cells loaded as dot-blot on membranes which were exposed to plasma and secondary antibody and developed by chemiluminescence analyses. The mean
intensity combining the results obtained for INF (n = 7) and REAC (n = 7) mice is shown. SM5-1 is human monoclonal antibody against gB used as a positive control.
Plasma of CTR mice showed no signal. (F) ELISA assay performed with mouse plasma. ELISA plates were coated with cell extracts generated with 293T, 293T-gB,
MRC-5, and MRC-5 infected with HCMV cells. Upper panel: Serial dilutions of the SM5-1 antibody was used as a reference in ELISA plates coated with 293TgB
extracts. Lower panels: 1/10 diluted plasma samples obtained from humanized mice administered with MRC-5 cells infected with HCMV/GLuc (HCMV-REAC) or
administered with MRC-5 cells infected with LV/GLuc (MRC-5-LV) (Exp. 2) were used. Reactivity of the antibodies were measured in the ELISA assay for absorbance
and depicted as OD450. Each data point represents results obtained for individual mice of the HCMV-REAC (n = 4) or MRC-5 LV (n = 4) cohort. Error bars indicate
standard deviation. Hatched line depicts the background signal of the assay.
optical imaging and PCR methodologies showed highest effects
of viral reactivations in LI, in SG and, remarkably, LN. LN-
like structures like the ones seen here were rarely documented
by other groups developing humanized mouse models, because
most of these studies were carried on using humanized mice too
soon (10–12 weeks) after HSCT, when they are not detectable.
The optical imaging approach provided a tool to directly point
to the main sites of HCMV infections and reactivations to
then study the systemic interplay between human T and B cell
responses.
The information about the human T/B immune modulation
in PBL was limited by the small volume of blood that could
be gained from the mice allowing only analyses of relative
cell frequencies, which were not very predictive. However,
the availability of several different tissues engrafted with high
numbers of human cells enabled a dynamic multidimensional
examination of the effects of HCMV infections. In order to
cope with the high dimensionality of multi-organ immune
phenotypic profiles and complexity of their relation to the
HCMV infection status, we employed PCA and LDA approaches
to identify the sets of markers able to predict REAC groups. We
employed different subsets of our experimental measurements
to obtain possible combinations of predicting markers. Our
analysis suggested that the structural differences of the HCMV
infection and reactivation were sufficiently captured by the
employed phenotypic markers, such that multiple subsets
of markers were able to distinguish and immunologically
explain the HCMV infection vs. reactivation status. Despite
certain degree of overlap between the sample distributions in
REAC and INF groups in our PCA analysis, the proposed
markers would be plausible candidates for training more
advanced machine learning techniques, such as artificial neural
networks, to improve big-data clustering for elucidating future
HCMV infections and reactivations models. However, LDA
as a linear multivariate statistical method was a quite robust
approach and sufficient to provide a clear separation between
different groups using T and/or B cell markers in spleen as
a single tissue to be analyzed. We tested the LDA results
in the blood, which corresponds to a relevant source of
clinical measurements in humans (Figure 6). T cell associated
measurements provided a satisfactory separation of REAC from
INF, whereas this separation was not obtained by PCA (data
not shown). The performance of multiple data classifiers is
generally evaluated and compared by using a validation data
set, which cannot be performed in an unbiased manner in
our study due to sample size limitation. Therefore, our LDA
analyses are preliminary attempt to evaluate the feasibility of
class separation and essential measurements using simple linear
classifiers. Overall, the clear message coming out of our model
with these combinations of analyses is that whereas primary
HCMV infections promoted robust memory T cell responses,
viral reactivations were associated with maturation/activation
of effector T cells (Figure 6). This is supported by findings
reported for the effects of HCMV in humans (12–14, 38, 39).
Furthermore, reactivations resulted into enhanced numbers of
PD-1+ CD4+ TE T cells in SPL and BM. This also corroborates
clinical observations, as for patients after HSCTs that were
non-viremic, with prolonged viremia or with CMV disease,
significant upregulation of PD-1 on T cells obtained from blood
was shown of the latest group (40). In our model, reactivations
seemed to be also associated with reduced total numbers of
effector CD8+ T cells, possibly because they were chronically
activated resulting into exhaustion and death. On the other
hand, infections stimulated B cell development, maturation
and class switch in several tissues. Nonetheless, these effects
were notably amplified by viral reactivations, probably as a
result of an improved CD4+ T cell maturation (Figure 6).
Combining the T and B cell responses derived from our model,
we can extrapolate to other clinical observations: Patients who
underwent a single reactivation generated significantly higher
amounts of CD4+ IFN-γ+ cells and humoral dominated immune
response (functional against gB), than did patients with multiple
reactivation episodes (15); after primary infections, HCMV-
neutralizing antibody levels were high in transplanted patients
from 6 to 12 months after transplant (16) and circulating
memory Tfh defined as CXCR5+ CD4+ cells were identified
concomitantly to both neutralizing and IgG antibodies to HCMV
glycoproteins (17, 41).
One important new finding observed in this model was
that HCMV infections promoted also thymic development of
CD4+ T cells and this was not lessened after viral reactivations.
The development of functional and HLA-restricted T cells
in humanized mice is currently perceived as enigmatic, since
the stroma cells that should provide antigenic stimulus, and
support for the TCR rearrangements during thymopoiesis in the
mouse thymus are mouse derived. Thus, they express mouse
(not human) major histocompatibility complexes (MHCs) and
the antigen presentation should be restricted to the mouse
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FIGURE 6 | Distinctive immunologic signatures observed in humanized mice after HCMV infections and reactivations. (A) LDA performed with panels of immune
phenotypic markers (frequencies % and absolute numbers #) used to characterize T and/or B cells measured in blood (BL) and spleen (SPL). The clusters show CTR
in gray, INF in blue, and REAC in red. The axes represent the percentage separation achieved by each discriminant function (LD1, LD2) according to a “proportion of
trace.” The top 5 markers with highest contributions (highest absolute coefficients) in the composition of discriminant functions are shown. Markers with negative and
positive contributions are annotated in blue and red, respectively. (B) Schematic representation of the data explaining the model: Relative to the control group,
infections promoted the development of memory CD4+ T cells whereas reactivations were strongly associated with expansion of effector CD4+ PD-1+ T cells and
development of IgG+ mature B cells.
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MHCs. Yet, in previous work using NRG mice humanized with
CB-CD34+ cells from HLA-A:02.01 donors and immunized
with matched induced DCs expressing pp65 (iDCpp65), we
obtained T cells from spleen or lymph nodes, expanded them
in vitro for a week with iDC or iDCpp65 and then preformed
the ELISpot using K562 cells expressing HLA-A ∗ 02:01 or
co-expressing pp65 and HLA-A ∗ 02:01 (26, 27). We could
conclusively demonstrate HLA-A ∗ 02:01-restricted responses
with these assays. The underlying mechanism remains as a
conundrum. In immunocompetent mice, the thymus supports
T-cell development, but also contains non-T-cell lineages such
as dendritic cells, macrophages, and granulocytes that are
necessary for T-cell repertoire selection and apoptotic thymocyte
clearance. Thus, we hypothesize that humanDCs or B considered
as good antigen presenting cells (APCs) highly expressing
class I and class II HLAs cells and trafficking or homing
in the thymus and could also support HLA-restricted T cell
development. The observed stimulation of thymic development
by HCMV observed here in humanized mice may be linked
to the presentation of HCMV antigens by human APCs to
early T cell progenitors. This may clarify the clinical paradox
whether HCMV reactivations and positive HCMV serology are
beneficial (42) or detrimental (43, 44) to stem cell recipients
regarding the “graft vs. leukemia” (GVL) effect, as this may be
time dependent. If HCMV reactivations occurs too early (5–
6 weeks after HSCT), CD4+ T cells development in thymus
may not be effective yet, whereas if HCMV reactivation
occurs later (such as in our humanized mouse model), it
might actually improve the overall development of CD4+
T cells to assist in GVL effects. Large retrospective clinical
studies concluded that HCMV reactivations occurring early after
mobilized blood- or CB-HSCT for patients with hematological
malignancies were associated with lower overall survival and
higher non-relapse mortality (43, 44). Paradoxically, others
reported that HCMV reactivations correlated with substantially
improved reduction of relapse incidence in patients with
acute myeloid leukemia (AML) after transplantation (42).
This phenomenon was explained either as a direct “virus-vs.-
leukemia” infection effect or as an indirect immune stimulatory
effect of HCMV on the innate and adaptive immune system
responses, which in turn could improve GVL effects. But
this conundrum is unresolved, as the descriptive nature of
these studies limited so far the identification of mechanisms
underlying the effects of HCMV infections or reactivations
in the immune system and vice-versa (45). Thus, a HCMV
mouse model combined with challenge of human leukemia could
provide a valuable experimental platform to examine the highly
disputed clinical enigma whether mechanisms of HCMV latency
and reactivations can combat or predispose human leukemia
development.
The data obtained in our humanized HCMV model also
supports early findings obtained by Jonjic et al. with mice
infected with murine CMV (MCMV), demonstrating that
B cells and probably antibodies restricted dissemination of
reactivated virus thus limiting recurrent infection (46). Using
the MCMV one of the co-authors in our studies recently
showed that a number of neutralizing anti-gB monoclonal
antibodies could bind to similar antigenic structures on MCMV-
gB that are represented in HCMV-gB, reducing viral burden in
immunodeficient RAG−/− hosts to limit an ongoing infection
(47). Our findings in humanized mice showed that B cell and
humoral responses were not inhibited by viral reactivations,
further endorsing the development of new vaccines boosting
humoral responses, as currently being evaluated in clinical trials
(48) or, alternatively, with adoptive administration of B cells
reactive against HCMV (49). On the other hand, we observed
that HCMV reactivations resulted into increased numbers of
terminally differentiated and activated CD8+PD-1+ cytotoxic
T lymphocytes (CTLs). This is important, as HCMV-reactive
adoptive memory CTLs used for HCMV immune cell therapy
(50–52) could potentially become chronically activated and
dysfunctional after infusion and migration to lymphatic tissues
harboring HCMV reactivation. Similarly as previously validated
for EBV pathologies in humanized mice (53), this novel HCMV
infection model and advanced multivariate analyses systems can
be used as proof-of-principle to evaluate innovative immune
therapies such as check-point inhibitors blocking PDL-1 and
CTLA-4.n the future, it will be interesting to evaluate the effects of
HCMV infections in immune deficient mouse strains expressing
human MHCs or multiple human cytokines (54).
Undoubtedly, there are several limitations associated with
humanized mouse models that remain to be addressed [recently
reviewed in (54)]. Structural limitations such as the mouse
stroma present in the thymus discussed above or the poorly
organized lymph nodes that are eventually repopulated with
human cells several weeks (>14) after HSCT are difficult to be
solved.
Nevertheless, a continued need exists to identify species-
specific differences between human and mouse cytokines and
other factors that are absent in mice and needed for human
immune cell differentiation and function. Thus, human cytokines
are being provided as administered recombinant factors, as
transgenic or knock-in approaches into mice. Providing human
IL-7 alone stimulated human T cell development in humanized
BALB/c-Rag2−/− mice, but did not support peripheral T cell
maintenance (55). Later, it was shown that naïve and memory
phenotype T cell subsets could be significantly increased by
exogenous administration of a potent human IL-15R agonist
into humanized (54) BALB/c-Rag2−/−γc−/− mice and this
was associated with improved humoral responses (56). More
recently, it was shown that provision of human IL-6 to knockin
mice (Rag2−/− γc−/−IL6h/h or with SIRPα knock-in Rag2−/−
γc−/− SIRPαh/m IL6h/h) humanized with fetal liver CD34+
cells injected into the liver of newborn mice greatly enhanced
human thymopoiesis, periphery T-cell development, and also
significantly increased class switched memory B cells and
serum IgG upon immunizations with OVA (57). As these new
approaches improve the human adaptive responses in humanized
mice, it would be interesting to evaluate in thesemodels the T and
B cell responses produced byHCMV infections and reactivations.
In addition, future humanized mouse models can be
further complemented with CB-matched human endothelial
or mesenchymal cells to promote and maintain HCMV lytic
cycles. The development of drugs used for prevention and
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treatment of HCMV infections after allo-HSCT has recently been
broadened from ganciclovir and foscarnet (58) to letermovir (57)
and maribavir (59). Nevertheless, these drugs have considerable
side effects (including immunological effects) in certain patient
populations and do not protect patients against later onset
HCMV infections. Passive immunization by administration of
HCMV immunoglobulin (CMVIG) preparations aims to restore
normal concentrations of HCMV-specific immunoglobulin in
the immunocompromised patient but data as monotherapy is
still limited and its mode of action in the immune system
is not yet fully understood (60, 61). Several HCMV-specific
monoclonal antibodies are in the research pipeline (62, 63) or
entering clinical trials for assessing efficacy, pharmacokinetic
and anti-drug antibody evaluations (64). Incremental advances
in the generation and selection of HCMV-reactive adoptive T
cells has convincingly improved the survival of high-risk patients
(50–52, 65, 66). Despite these pharmacologic and immune
cell therapies, HCMV disease can still cause considerable
morbidity and mortality (3–5). Availability of reproducible and
predictive humanized mouse models of HCMV infections and
reactivations such as the one shown here are therefore required to
demonstrate proof-of-concept, efficacy and safety of single agent
or combination therapies.
In summary, this novel humanized mouse model
recapitulated and differentiated HCMV primary infections
and reactivations after HSCT and showed multifaceted
tissue-dependent patterns of immune modulatory effects.
Convincingly, it showed that HCMV infections and reactivations
resulted functional T and B cell responses against HCMV
antigens which could be split into distinct signatures: infections
promoted differentiation and activation of memory T cells
whereas reactivations promoted differentiation and maturation
of B cells. Our data suggest that PD-1 upregulation is predictive
of HCMV reactivations and can become a practical and useful
biomarker. In summary, this novel experimental model allied
with multivariate analyses reflects the complexity and diversity of
clinical outcomes after HCMV infections and reactivations and
can be explored for testing efficacy of novel antiviral therapies
and vaccines.
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